✦ LIBER ✦

Exemestane may be as effective as tamoxifen in the first-line treatment of postmenopausal women with advanced breast cancer,

Book ID: 120870372
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2000
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200012400-00043

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anastrozole is just as effective and may

Anastrozole is just as effective and may have fewer side-effects than tamoxifen in first-line treatment of advanced postmenopausal breast cancer: Anastrozole is at least as effective as tamoxifen in first-line treatment of advanced postmenopausal breast cancer

✍ Gerald M. Higa 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 335 KB

Cost-effectiveness of anastrozole versus

Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer

✍ W.Robert Simons; David Jones; Aman Buzdar 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 175 KB

Efficacy of tamoxifen following anastroz

Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women

✍ B. Thürlimann; J.F.R. Robertson; J.M. Nabholtz; A. Buzdar; J. Bonneterre 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 247 KB

Randomised study of anastrozole versus t

Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women

✍ I. Vergote; J. Bonneterre; B. Thürlimann; J. Robertson; M. Krzakowski; L. Mauria 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Phase III Study Comparing Exemestane Wit

Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

✍ Ma, C.X.; Ellis, M.J. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 174 KB

Cost-effectiveness of switching to exeme

Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer

✍ Nancy A. Risebrough; Shailendra Verma; Maureen Trudeau; Nicole Mittmann 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

## Abstract ## BACKGROUND. Sequential tamoxifen/exemestane therapy reportedly improves disease‐free survival in women with primary breast cancer compared with continued tamoxifen therapy. The objective of the current study was to assess the cost‐effectiveness of switching to exemestane after 2 to